Biogen (BIIB) Well Positioned After FDA Grants Priority Review - Canaccord Genuity

August 7, 2020 12:27 PM
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $350.00 price target on Biogen (NASDAQ: BIIB), citing the FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles